Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size, Status and Forecast 2024-2031

Report ID: 918380 | Published Date: Jan 2025 | No. of Page: 106 | Base Year: 2024 | Rating: 4.2 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Report Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
        1.2.2 Drugs
        1.2.3 Devices
    1.3 Market by Application
        1.3.1 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Application: 2016 VS 2021 VS 2027
        1.3.2 Hospitals
        1.3.3 Clinics
        1.3.4 Others
    1.4 Study Objectives
    1.5 Years Considered

2 Global Growth Trends
    2.1 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Perspective (2016-2027)
    2.2 Benign Prostatic Hyperplasia (BPH) Treatment Growth Trends by Regions
        2.2.1 Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Regions: 2016 VS 2021 VS 2027
        2.2.2 Benign Prostatic Hyperplasia (BPH) Treatment Historic Market Share by Regions (2016-2021)
        2.2.3 Benign Prostatic Hyperplasia (BPH) Treatment Forecasted Market Size by Regions (2022-2027)
    2.3 Benign Prostatic Hyperplasia (BPH) Treatment Industry Dynamic
        2.3.1 Benign Prostatic Hyperplasia (BPH) Treatment Market Trends
        2.3.2 Benign Prostatic Hyperplasia (BPH) Treatment Market Drivers
        2.3.3 Benign Prostatic Hyperplasia (BPH) Treatment Market Challenges
        2.3.4 Benign Prostatic Hyperplasia (BPH) Treatment Market Restraints

3 Competition Landscape by Key Players
    3.1 Global Top Benign Prostatic Hyperplasia (BPH) Treatment Players by Revenue
        3.1.1 Global Top Benign Prostatic Hyperplasia (BPH) Treatment Players by Revenue (2016-2021)
        3.1.2 Global Benign Prostatic Hyperplasia (BPH) Treatment Revenue Market Share by Players (2016-2021)
    3.2 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    3.3 Players Covered: Ranking by Benign Prostatic Hyperplasia (BPH) Treatment Revenue
    3.4 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Concentration Ratio
        3.4.1 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Benign Prostatic Hyperplasia (BPH) Treatment Revenue in 2020
    3.5 Benign Prostatic Hyperplasia (BPH) Treatment Key Players Head office and Area Served
    3.6 Key Players Benign Prostatic Hyperplasia (BPH) Treatment Product Solution and Service
    3.7 Date of Enter into Benign Prostatic Hyperplasia (BPH) Treatment Market
    3.8 Mergers & Acquisitions, Expansion Plans

4 Benign Prostatic Hyperplasia (BPH) Treatment Breakdown Data by Type
    4.1 Global Benign Prostatic Hyperplasia (BPH) Treatment Historic Market Size by Type (2016-2021)
    4.2 Global Benign Prostatic Hyperplasia (BPH) Treatment Forecasted Market Size by Type (2022-2027)

5 Benign Prostatic Hyperplasia (BPH) Treatment Breakdown Data by Application
    5.1 Global Benign Prostatic Hyperplasia (BPH) Treatment Historic Market Size by Application (2016-2021)
    5.2 Global Benign Prostatic Hyperplasia (BPH) Treatment Forecasted Market Size by Application (2022-2027)

6 North America
    6.1 North America Benign Prostatic Hyperplasia (BPH) Treatment Market Size (2016-2027)
    6.2 North America Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type
        6.2.1 North America Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type (2016-2021)
        6.2.2 North America Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type (2022-2027)
        6.2.3 North America Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type (2016-2027)
    6.3 North America Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application
        6.3.1 North America Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application (2016-2021)
        6.3.2 North America Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application (2022-2027)
        6.3.3 North America Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application (2016-2027)
    6.4 North America Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Country
        6.4.1 North America Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Country (2016-2021)
        6.4.2 North America Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Country (2022-2027)
        6.4.3 United States
        6.4.4 Canada

7 Europe
    7.1 Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size (2016-2027)
    7.2 Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type
        7.2.1 Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type (2016-2021)
        7.2.2 Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type (2022-2027)
        7.2.3 Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type (2016-2027)
    7.3 Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application
        7.3.1 Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application (2016-2021)
        7.3.2 Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application (2022-2027)
        7.3.3 Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application (2016-2027)
    7.4 Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Country
        7.4.1 Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Country (2016-2021)
        7.4.2 Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Country (2022-2027)
        7.4.3 Germany
        7.4.4 France
        7.4.5 U.K.
        7.4.6 Italy
        7.4.7 Russia
        7.4.8 Nordic

8 Asia-Pacific
    8.1 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Market Size (2016-2027)
    8.2 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type
        8.2.1 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type (2016-2021)
        8.2.2 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type (2022-2027)
        8.2.3 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type (2016-2027)
    8.3 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application
        8.3.1 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application (2016-2021)
        8.3.2 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application (2022-2027)
        8.3.3 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application (2016-2027)
    8.4 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Region
        8.4.1 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Region (2016-2021)
        8.4.2 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Region (2022-2027)
        8.4.3 China
        8.4.4 Japan
        8.4.5 South Korea
        8.4.6 Southeast Asia
        8.4.7 India
        8.4.8 Australia

9 Latin America
    9.1 Latin America Benign Prostatic Hyperplasia (BPH) Treatment Market Size (2016-2027)
    9.2 Latin America Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type
        9.2.1 Latin America Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type (2016-2021)
        9.2.2 Latin America Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type (2022-2027)
        9.2.3 Latin America Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type (2016-2027)
    9.3 Latin America Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application
        9.3.1 Latin America Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application (2016-2021)
        9.3.2 Latin America Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application (2022-2027)
        9.3.3 Latin America Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application (2016-2027)
    9.4 Latin America Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Country
        9.4.1 Latin America Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Country (2016-2021)
        9.4.2 Latin America Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Country (2022-2027)
        9.4.3 Mexico
        9.4.4 Brazil

10 Middle East & Africa
    10.1 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Size (2016-2027)
    10.2 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type
        10.2.1 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type (2016-2021)
        10.2.2 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type (2022-2027)
        10.2.3 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type (2016-2027)
    10.3 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application
        10.3.1 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application (2016-2021)
        10.3.2 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application (2022-2027)
        10.3.3 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application (2016-2027)
    10.4 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Country
        10.4.1 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Country (2016-2021)
        10.4.2 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Country (2022-2027)
        10.4.3 Turkey
        10.4.4 Saudi Arabia
        10.4.5 UAE

11 Key Players Profiles
    11.1 Pfizer
        11.1.1 Pfizer Company Details
        11.1.2 Pfizer Business Overview
        11.1.3 Pfizer Benign Prostatic Hyperplasia (BPH) Treatment Introduction
        11.1.4 Pfizer Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2016-2021)
        11.1.5 Pfizer Recent Development
    11.2 Sanofi
        11.2.1 Sanofi Company Details
        11.2.2 Sanofi Business Overview
        11.2.3 Sanofi Benign Prostatic Hyperplasia (BPH) Treatment Introduction
        11.2.4 Sanofi Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2016-2021)
        11.2.5 Sanofi Recent Development
    11.3 GlaxoSmithKline
        11.3.1 GlaxoSmithKline Company Details
        11.3.2 GlaxoSmithKline Business Overview
        11.3.3 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Treatment Introduction
        11.3.4 GlaxoSmithKline Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2016-2021)
        11.3.5 GlaxoSmithKline Recent Development
    11.4 Boston Scientific
        11.4.1 Boston Scientific Company Details
        11.4.2 Boston Scientific Business Overview
        11.4.3 Boston Scientific Benign Prostatic Hyperplasia (BPH) Treatment Introduction
        11.4.4 Boston Scientific Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2016-2021)
        11.4.5 Boston Scientific Recent Development
    11.5 Teleflex
        11.5.1 Teleflex Company Details
        11.5.2 Teleflex Business Overview
        11.5.3 Teleflex Benign Prostatic Hyperplasia (BPH) Treatment Introduction
        11.5.4 Teleflex Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2016-2021)
        11.5.5 Teleflex Recent Development
    11.6 Cardinal Health
        11.6.1 Cardinal Health Company Details
        11.6.2 Cardinal Health Business Overview
        11.6.3 Cardinal Health Benign Prostatic Hyperplasia (BPH) Treatment Introduction
        11.6.4 Cardinal Health Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2016-2021)
        11.6.5 Cardinal Health Recent Development
    11.7 Allergan
        11.7.1 Allergan Company Details
        11.7.2 Allergan Business Overview
        11.7.3 Allergan Benign Prostatic Hyperplasia (BPH) Treatment Introduction
        11.7.4 Allergan Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2016-2021)
        11.7.5 Allergan Recent Development
    11.8 Teva Pharmaceutical
        11.8.1 Teva Pharmaceutical Company Details
        11.8.2 Teva Pharmaceutical Business Overview
        11.8.3 Teva Pharmaceutical Benign Prostatic Hyperplasia (BPH) Treatment Introduction
        11.8.4 Teva Pharmaceutical Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2016-2021)
        11.8.5 Teva Pharmaceutical Recent Development
    11.9 Mylan
        11.9.1 Mylan Company Details
        11.9.2 Mylan Business Overview
        11.9.3 Mylan Benign Prostatic Hyperplasia (BPH) Treatment Introduction
        11.9.4 Mylan Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2016-2021)
        11.9.5 Mylan Recent Development
    11.10 Eli Lilly
        11.10.1 Eli Lilly Company Details
        11.10.2 Eli Lilly Business Overview
        11.10.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Treatment Introduction
        11.10.4 Eli Lilly Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2016-2021)
        11.10.5 Eli Lilly Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Disclaimer
    13.3 Author Details
List of Tables
    Table 1. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
    Table 2. Key Players of Drugs
    Table 3. Key Players of Devices
    Table 4. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
    Table 5. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
    Table 6. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Regions (2016-2021) & (US$ Million)
    Table 7. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Regions (2016-2021)
    Table 8. Global Benign Prostatic Hyperplasia (BPH) Treatment Forecasted Market Size by Regions (2022-2027) & (US$ Million)
    Table 9. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Regions (2022-2027)
    Table 10. Benign Prostatic Hyperplasia (BPH) Treatment Market Trends
    Table 11. Benign Prostatic Hyperplasia (BPH) Treatment Market Drivers
    Table 12. Benign Prostatic Hyperplasia (BPH) Treatment Market Challenges
    Table 13. Benign Prostatic Hyperplasia (BPH) Treatment Market Restraints
    Table 14. Global Benign Prostatic Hyperplasia (BPH) Treatment Revenue by Players (2016-2021) & (US$ Million)
    Table 15. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Players (2016-2021)
    Table 16. Global Top Benign Prostatic Hyperplasia (BPH) Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Benign Prostatic Hyperplasia (BPH) Treatment as of 2020)
    Table 17. Ranking of Global Top Benign Prostatic Hyperplasia (BPH) Treatment Companies by Revenue (US$ Million) in 2020
    Table 18. Global 5 Largest Players Market Share by Benign Prostatic Hyperplasia (BPH) Treatment Revenue (CR5 and HHI) & (2016-2021)
    Table 19. Key Players Headquarters and Area Served
    Table 20. Key Players Benign Prostatic Hyperplasia (BPH) Treatment Product Solution and Service
    Table 21. Date of Enter into Benign Prostatic Hyperplasia (BPH) Treatment Market
    Table 22. Mergers & Acquisitions, Expansion Plans
    Table 23. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type (2016-2021) (US$ Million)
    Table 24. Global Benign Prostatic Hyperplasia (BPH) Treatment Revenue Market Share by Type (2016-2021)
    Table 25. Global Benign Prostatic Hyperplasia (BPH) Treatment Forecasted Market Size by Type (2022-2027) (US$ Million)
    Table 26. Global Benign Prostatic Hyperplasia (BPH) Treatment Revenue Market Share by Type (2022-2027) & (US$ Million)
    Table 27. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size Share by Application (2016-2021) & (US$ Million)
    Table 28. Global Benign Prostatic Hyperplasia (BPH) Treatment Revenue Market Share by Application (2016-2021)
    Table 29. Global Benign Prostatic Hyperplasia (BPH) Treatment Forecasted Market Size by Application (2022-2027) (US$ Million)
    Table 30. Global Benign Prostatic Hyperplasia (BPH) Treatment Revenue Market Share by Application (2022-2027) & (US$ Million)
    Table 31. North America Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type (2016-2021) (US$ Million)
    Table 32. North America Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type (2022-2027) & (US$ Million)
    Table 33. North America Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application (2016-2021) (US$ Million)
    Table 34. North America Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application (2022-2027) & (US$ Million)
    Table 35. North America Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Country (2016-2021) & (US$ Million) 
    Table 36. North America Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Country (2022-2027) & (US$ Million) 
    Table 37. Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type (2016-2021) (US$ Million)
    Table 38. Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type (2022-2027) & (US$ Million)
    Table 39. Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application (2016-2021) (US$ Million)
    Table 40. Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application (2022-2027) & (US$ Million)
    Table 41. Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Country (2016-2021) & (US$ Million) 
    Table 42. Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Country (2022-2027) & (US$ Million) 
    Table 43. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type (2016-2021) (US$ Million)
    Table 44. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type (2022-2027) & (US$ Million)
    Table 45. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application (2016-2021) (US$ Million)
    Table 46. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application (2022-2027) & (US$ Million)
    Table 47. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Region (2016-2021) & (US$ Million) 
    Table 48. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Region (2022-2027) & (US$ Million) 
    Table 49. Latin America Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type (2016-2021) (US$ Million)
    Table 50. Latin America Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type (2022-2027) & (US$ Million)
    Table 51. Latin America Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application (2016-2021) (US$ Million)
    Table 52. Latin America Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application (2022-2027) & (US$ Million)
    Table 53. Latin America Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Country (2016-2021) & (US$ Million) 
    Table 54. Latin America Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Country (2022-2027) & (US$ Million) 
    Table 55. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type (2016-2021) (US$ Million)
    Table 56. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type (2022-2027) & (US$ Million)
    Table 57. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application (2016-2021) (US$ Million)
    Table 58. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application (2022-2027) & (US$ Million)
    Table 59. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Country (2016-2021) & (US$ Million) 
    Table 60. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Country (2022-2027) & (US$ Million) 
    Table 61. Pfizer Company Details
    Table 62. Pfizer Business Overview
    Table 63. Pfizer Benign Prostatic Hyperplasia (BPH) Treatment Product
    Table 64. Pfizer Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2016-2021) & (US$ Million)
    Table 65. Pfizer Recent Development
    Table 66. Sanofi Company Details
    Table 67. Sanofi Business Overview
    Table 68. Sanofi Benign Prostatic Hyperplasia (BPH) Treatment Product
    Table 69. Sanofi Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2016-2021) & (US$ Million)
    Table 70. Sanofi Recent Development
    Table 71. GlaxoSmithKline Company Details
    Table 72. GlaxoSmithKline Business Overview
    Table 73. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Treatment Product
    Table 74. GlaxoSmithKline Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2016-2021) & (US$ Million)
    Table 75. GlaxoSmithKline Recent Development
    Table 76. Boston Scientific Company Details
    Table 77. Boston Scientific Business Overview
    Table 78. Boston Scientific Benign Prostatic Hyperplasia (BPH) Treatment Product
    Table 79. Boston Scientific Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2016-2021) & (US$ Million)
    Table 80. Boston Scientific Recent Development
    Table 81. Teleflex Company Details
    Table 82. Teleflex Business Overview
    Table 83. Teleflex Benign Prostatic Hyperplasia (BPH) Treatment Product
    Table 84. Teleflex Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2016-2021) & (US$ Million)
    Table 85. Teleflex Recent Development
    Table 86. Cardinal Health Company Details
    Table 87. Cardinal Health Business Overview
    Table 88. Cardinal Health Benign Prostatic Hyperplasia (BPH) Treatment Product
    Table 89. Cardinal Health Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2016-2021) & (US$ Million)
    Table 90. Cardinal Health Recent Development
    Table 91. Allergan Company Details
    Table 92. Allergan Business Overview
    Table 93. Allergan Benign Prostatic Hyperplasia (BPH) Treatment Product
    Table 94. Allergan Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2016-2021) & (US$ Million)
    Table 95. Allergan Recent Development
    Table 96. Teva Pharmaceutical Company Details
    Table 97. Teva Pharmaceutical Business Overview
    Table 98. Teva Pharmaceutical Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2016-2021) & (US$ Million)
    Table 99. Teva Pharmaceutical Recent Development
    Table 100. Mylan Company Details
    Table 101. Mylan Business Overview
    Table 102. Mylan Benign Prostatic Hyperplasia (BPH) Treatment Product
    Table 103. Mylan Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2016-2021) & (US$ Million)
    Table 104. Mylan Recent Development
    Table 105. Eli Lilly Company Details
    Table 106. Eli Lilly Business Overview
    Table 107. Eli Lilly Benign Prostatic Hyperplasia (BPH) Treatment Product
    Table 108. Eli Lilly Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2016-2021) & (US$ Million)
    Table 109. Eli Lilly Recent Development
    Table 110. Research Programs/Design for This Report
    Table 111. Key Data Information from Secondary Sources
    Table 112. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Type: 2020 VS 2027
    Figure 2. Drugs Features
    Figure 3. Devices Features
    Figure 4. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Application: 2020 VS 2027
    Figure 5. Hospitals Case Studies
    Figure 6. Clinics Case Studies
    Figure 7. Others Case Studies
    Figure 8. Benign Prostatic Hyperplasia (BPH) Treatment Report Years Considered
    Figure 9. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size (US$ Million), Year-over-Year: 2016-2027
    Figure 10. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size (US$ Million), 2016 VS 2021 VS 2027
    Figure 11. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Regions: 2020 VS 2027
    Figure 12. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Regions (2022-2027)
    Figure 13. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Players in 2020
    Figure 14. Global Top Benign Prostatic Hyperplasia (BPH) Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Benign Prostatic Hyperplasia (BPH) Treatment as of 2020
    Figure 15. The Top 10 and 5 Players Market Share by Benign Prostatic Hyperplasia (BPH) Treatment Revenue in 2020
    Figure 16. Global Benign Prostatic Hyperplasia (BPH) Treatment Revenue Market Share by Type (2016-2021)
    Figure 17. Global Benign Prostatic Hyperplasia (BPH) Treatment Revenue Market Share by Type (2022-2027)
    Figure 18. North America Benign Prostatic Hyperplasia (BPH) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 19. North America Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Type (2016-2027)
    Figure 20. North America Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Application (2016-2027)
    Figure 21. North America Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Country (2016-2027)
    Figure 22. United States Benign Prostatic Hyperplasia (BPH) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 23. Canada Benign Prostatic Hyperplasia (BPH) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 24. Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 25. Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Type (2016-2027)
    Figure 26. Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Application (2016-2027)
    Figure 27. Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Country (2016-2027)
    Figure 28. Germany Benign Prostatic Hyperplasia (BPH) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 29. France Benign Prostatic Hyperplasia (BPH) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 30. U.K. Benign Prostatic Hyperplasia (BPH) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 31. Italy Benign Prostatic Hyperplasia (BPH) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 32. Russia Benign Prostatic Hyperplasia (BPH) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 33. Nordic Benign Prostatic Hyperplasia (BPH) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 34. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 35. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Type (2016-2027)
    Figure 36. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Application (2016-2027)
    Figure 37. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Region (2016-2027)
    Figure 38. China Benign Prostatic Hyperplasia (BPH) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 39. Japan Benign Prostatic Hyperplasia (BPH) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 40. South Korea Benign Prostatic Hyperplasia (BPH) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 41. Southeast Asia Benign Prostatic Hyperplasia (BPH) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 42. India Benign Prostatic Hyperplasia (BPH) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 43. Australia Benign Prostatic Hyperplasia (BPH) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 44. Latin America Benign Prostatic Hyperplasia (BPH) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 45. Latin America Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Type (2016-2027)
    Figure 46. Latin America Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Application (2016-2027)
    Figure 47. Latin America Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Country (2016-2027)
    Figure 48. Mexico Benign Prostatic Hyperplasia (BPH) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 49. Brazil Benign Prostatic Hyperplasia (BPH) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 50. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 51. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Type (2016-2027)
    Figure 52. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Application (2016-2027)
    Figure 53. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Country (2016-2027)
    Figure 54. Turkey Benign Prostatic Hyperplasia (BPH) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 55. Saudi Arabia Benign Prostatic Hyperplasia (BPH) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 56. UAE Benign Prostatic Hyperplasia (BPH) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 57. Pfizer Revenue Growth Rate in Benign Prostatic Hyperplasia (BPH) Treatment Business (2016-2021)
    Figure 58. Sanofi Revenue Growth Rate in Benign Prostatic Hyperplasia (BPH) Treatment Business (2016-2021)
    Figure 59. GlaxoSmithKline Revenue Growth Rate in Benign Prostatic Hyperplasia (BPH) Treatment Business (2016-2021)
    Figure 60. Boston Scientific Revenue Growth Rate in Benign Prostatic Hyperplasia (BPH) Treatment Business (2016-2021)
    Figure 61. Teleflex Revenue Growth Rate in Benign Prostatic Hyperplasia (BPH) Treatment Business (2016-2021)
    Figure 62. Cardinal Health Revenue Growth Rate in Benign Prostatic Hyperplasia (BPH) Treatment Business (2016-2021)
    Figure 63. Allergan Revenue Growth Rate in Benign Prostatic Hyperplasia (BPH) Treatment Business (2016-2021)
    Figure 64. Teva Pharmaceutical Revenue Growth Rate in Benign Prostatic Hyperplasia (BPH) Treatment Business (2016-2021)
    Figure 65. Mylan Revenue Growth Rate in Benign Prostatic Hyperplasia (BPH) Treatment Business (2016-2021)
    Figure 66. Eli Lilly Revenue Growth Rate in Benign Prostatic Hyperplasia (BPH) Treatment Business (2016-2021)
    Figure 67. Bottom-up and Top-down Approaches for This Report
    Figure 68. Data Triangulation
    Figure 69. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Pfizer
Sanofi
GlaxoSmithKline
Boston Scientific
Teleflex
Cardinal Health
Allergan
Teva Pharmaceutical
Mylan
Eli Lilly
Frequently Asked Questions
Benign Prostatic Hyperplasia (BPH) Treatment report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Benign Prostatic Hyperplasia (BPH) Treatment report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Benign Prostatic Hyperplasia (BPH) Treatment report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports

Elderly Nutrition

Elderly Nutrition applies nutrition principles to delay effects of aging and disease, to aid in t ... Read More